TC
ARGS

TFS Capital’s Argos Therapeutics, Inc. ARGS Stock Holding History

TFS Capital’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-561
Closed -$72K – 1389
2016
Q1 		$72K Buy
+561
New +$45.4K 0.01% 929

Other funds holding ARGS

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFS Capital's ARGS Position: Q2 2016 in Review

TFS Capital sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2016, closing a stake of 561 shares — an estimated $72K sold.

TFS Capital first reported a position in ARGS in Q1 2016 and held it in 1 quarter. The position peaked at $72K in Q1 2016. 43 funds tracked by Wall St. Rank hold ARGS as of Q2 2016.

  • TFS Capital reported no remaining Argos Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 561 Argos Therapeutics, Inc. shares in Q2 2016, an estimated $72K.
  • TFS Capital first reported a position in Argos Therapeutics, Inc. in Q1 2016 and held it in 1 quarter.
  • TFS Capital's Argos Therapeutics, Inc. position peaked at $72K in Q1 2016.
  • 43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.